Neurology

Yesterday Biogen Idec announced the company has submitted a New Drug Application (NDA) to the FDA for marketing approval of BG-12 (dimethyl fumarate), the company's oral therapeutic candidate for the treatment of multiple sclerosis (MS).

This complicated central nervous system disorder has many types and varying symptoms, and new treatments are available to help.

Pharmacies in the community setting have led the way in patient compliance, but have been largely ignored by MCOs and the pharmaceutical industry.

When insomnia begins to negatively impact a patient's quality of life, pharmacists can explain the nonpharmalogic and pharmalogic treatment options.

When insomnia begins to negatively impact a patient's quality of life, pharmacists can explain the nonpharmalogic and pharmalogic treatment options.

Exciting advances in the treatment of multiple sclerosis (MS) occurred in 2010 and continue as the MS pipeline remains robust.

This article will help patients with depression to understand their treatment options and know what to expect from their medications.

This article will help patients with depression to understand their treatment options and know what to expect from their medications.

New guidelines for managing patients with atrial fibrillation emphasize stroke prevention.

Stroke affects nearly 700,000 Americans a year. Emergency management is key to a positive patient outcome.